ARVO 2024: Detection of glaucoma with a novel widefield imaging device combined with OCT
May 16th 2024At this year's ARVO meeting, Michael Chaglasian, OD, spoke with Ophthalmology Times about the paper he presented on the detection of glaucoma with a novel widefield imaging device combined with OCT
Read More
Prevent Blindness kicks off ‘It Started With an Eye Exam’
May 16th 2024The campaign will encourage, educate and empower the public to include vision and eye health as a part of their healthcare by asking them to share how eye care services and exams improved their vision and their daily lives.
Read More
ARVO 2024: Abnormal subendothelial matrix exacerbates choroidal endothelial cell death in early AMD
May 16th 2024At this year's ARVO meeting, Irene Santiago Tierno, MS, talked with Ophthalmology Times about the paper she presented on how abnormal subendothelial matrix exacerbates choroidal endothelial cell death in early age-related macular degeneration.
Read More
ARVO 2024: Exploratory analysis of pivotal phase 3 trials, YOSEMITE and RHINE, for vabysmo in DME
May 15th 2024At this year's ARVO meeting, Daniela Ferrara, MD, PhD, FASRS, presented a paper on predicting functional outcomes for different treatment durations of faricimab in Diabetic macular edema.
Read More
Study: Virus that causes COVID-19 can penetrate blood-retinal barrier and may damage vision
May 15th 2024Researchers at the University of Missouri School of Medicine have conducted a study in a humanized mouse model to show that infections can occur deep inside the eye by penetrating the blood-retinal barrier.
Read More
ARVO 2024: Reduction in hard exudates with faricimab vs aflibercept in patients with DME
May 15th 2024At this year's ARVO meeting, Roger Goldberg, MD, presented a paper on hard exudates and their resolution in patients with diabetic macular edema treated with either faricimab or 2 mg aflibercept.
Read More
Researchers: ‘Smart’ contact lenses may one day enable wireless glaucoma detection
May 13th 2024A team of Chinese researchers have been working on a way to continuously and more comfortably detect these tiny fluctuations in pressure, such as contact lenses that transmit signals to receptor glasses.
Read More
ARVO 2024: Predicting 3-year myopia control efficacy from 1-year data
May 11th 2024At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Noel Brennan, MScOptom, PhD. The clinical research fellow at Johnson and Johnson shared highlights from his presentation on myopia control and predictive modeling.
Read More
At this year's ARVO meeting in Seattle, Washington, Dolly Chang, MD, PhD, presented data on the early fluid reduction in patients with diabetic macular edema, and how that correlates with 1-year outcome with a deep learning-based retina segmentation tool using the Phase 2 BOULEVARD trial.
Read More
ARVO 2024: Impact of switching when using an aflibercept biosimilar
May 9th 2024SriniVas R Sadda, MD, presented "Post Hoc Analysis of a Phase 3 Trial on SB15 (Proposed Aflibercept Biosimilar): Assessment on Pre-to-Post Switching Efficacy and Safety in Neovascular Age-related Macular Degeneration."
Read More
ARVO 2024: A study on multi-ingredient oral supplement for dry eye symptoms and tear volume
May 7th 2024Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9, on a multi-ingredient oral supplement on dry eye symptoms and tear volume.
Read More
ARVO 2024: Post-hoc analysis of GOBI and MOJAVE trials for perfluorohexyloctane
May 7th 2024John Sheppard, MD, MSc, FACs, sat down to discuss post-hoc analysis of 2 FDA registration trials for perfluorohexyloctane, GOBI and MOJAVE, at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.
Read More